Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Ipsen upgraded to Buy from Neutral at Bryan Garnier » 05:36
06/08/20
06/08
05:36
06/08/20
05:36
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Bryan Garnier analyst…

Bryan Garnier analyst Eric Le Berrigaud upgraded Ipsen to Buy from Neutral with a EUR 96 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Over a month ago
Recommendations
Ipsen price target raised to EUR 72 from EUR 62 at Barclays » 14:18
06/01/20
06/01
14:18
06/01/20
14:18
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Ipsen to EUR 72 from EUR 62 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Upgrade
Ipsen upgraded to Buy from Neutral at BofA » 05:42
06/01/20
06/01
05:42
06/01/20
05:42
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

BofA upgraded Ipsen to…

BofA upgraded Ipsen to Buy from Neutral with a EUR 90 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Upgrade
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan » 06:39
05/18/20
05/18
06:39
05/18/20
06:39
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser upgraded Ipsen to Neutral from Underweight with a price target of EUR 70, up from EUR 65. The market appropriately values the potential for Cabometyx in renal cell carcinoma, suggesting limited downside from current share levels, Vosser tells investors in a research note. However, while there could be upside from Cabometyx in hepatocellular carcinoma, it is not sufficient to drive Ipsen to a position of sustainable growth, adds the analyst.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
04/20/20 Barclays
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Upgrade
Ipsen upgraded to Neutral from Underweight at JPMorgan » 04:39
05/18/20
05/18
04:39
05/18/20
04:39
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser upgraded Ipsen to Neutral from Underweight with a EUR 70 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
04/20/20 Barclays
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays
02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Upgrade
Ipsen upgraded to Buy from Neutral at Oddo BHF » 05:32
04/23/20
04/23
05:32
04/23/20
05:32
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Oddo BHF analyst…

Oddo BHF analyst Christophe-Raphael Ganet upgraded Ipsen to Buy from Neutral with a EUR 71 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
04/20/20 Barclays
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays
02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
01/09/20 Jefferies
Ipsen downgraded to Hold from Buy at Jefferies
Recommendations
Ipsen price target raised to EUR 99 from EUR 90 at UBS » 12:10
04/22/20
04/22
12:10
04/22/20
12:10
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

UBS analyst Michael…

UBS analyst Michael Leutchen raised the firm's price target on Ipsen to EUR 99 from EUR 90 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

04/20/20 Barclays
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays
02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
01/09/20 Jefferies
Ipsen downgraded to Hold from Buy at Jefferies
01/05/20 JPMorgan
Ipsen downgraded to Underweight from Neutral at JPMorgan
Recommendations
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays » 11:42
04/20/20
04/20
11:42
04/20/20
11:42
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Barclays analyst Emily…

Barclays analyst Emily Field lowered the firm's price target on Ipsen to EUR 62 from EUR 68 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
01/09/20 Jefferies
Ipsen downgraded to Hold from Buy at Jefferies
01/05/20 JPMorgan
Ipsen downgraded to Underweight from Neutral at JPMorgan
12/09/19 Barclays
Ipsen downgraded to Equal Weight from Overweight at Barclays
On The Fly
Immunomedics doubles after cancer drug trial stops early on 'remarkable' results » 10:46
04/06/20
04/06
10:46
04/06/20
10:46
IMMU

Immunomedics

$19.01 /

+9.62 (+102.45%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Shares of Immunomedics…

Open Full Text

ShowHide Related Items >><<
IMMU Immunomedics
$19.01 /

+9.62 (+102.45%)

04/07/20 H.C. Wainwright
Immunomedics price target raised to $34 from $31 at H.C. Wainwright
04/06/20 Piper Sandler
Immunomedics price target raised to $30 from $25 at Piper Sandler
04/06/20 Goldman Sachs
Immunomedics early stop for SG trial a 'clear positive,' says Goldman Sachs
04/06/20 Jefferies
Immunomedics trial stop a 'major' de-risking event, says Jefferies
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
01/09/20 Jefferies
Ipsen downgraded to Hold from Buy at Jefferies
01/05/20 JPMorgan
Ipsen downgraded to Underweight from Neutral at JPMorgan
12/09/19 Barclays
Ipsen downgraded to Equal Weight from Overweight at Barclays
Hot Stocks
Immunomedics appoints Harout Semerjian as president, CEO » 07:52
04/06/20
04/06
07:52
04/06/20
07:52
IMMU

Immunomedics

$9.39 /

-1.25 (-11.75%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Immunomedics (IMMU)…

Immunomedics (IMMU) announced that its Board of Directors has appointed Harout Semerjian as President and CEO and as a member of the Board, effective April 16, 2020. Most recently, he served as EVP, CCO at Ipsen (IPSEY) where he was accountable for the worldwide commercialization and portfolio strategy across oncology, neurosciences and rare diseases, as well as leading specialty operations across Europe and International markets, overseeing 2,200 employees in over 30 countries. With the appointment of Mr. Semerjian and effective as of the commencement date of Mr. Semerjian's employment, Mr. Scott Canute will step down from his role as Executive Director and resume his role as a Board member, while Dr. Aghazadeh will remain as Executive Chairman focusing on corporate strategy and business development and, during a transition period, will continue to interface with the investment community on behalf of the Company.

ShowHide Related Items >><<
IMMU Immunomedics
$9.39 /

-1.25 (-11.75%)

04/03/20
Fly Intel: Top five analyst downgrades
04/03/20 Goldman Sachs
Immunomedics downgraded to Sell from Buy at Goldman Sachs
04/02/20 H.C. Wainwright
Immunomedics launch delay beyond 12 months unlikely, says H.C. Wainwright
04/01/20 Piper Sandler
Immunomedics says many issues in 483 already addressed, says Piper Sandler
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/11/20 Credit Suisse
Ipsen upgraded to Neutral from Underperform at Credit Suisse
01/09/20 Jefferies
Ipsen downgraded to Hold from Buy at Jefferies
01/05/20 JPMorgan
Ipsen downgraded to Underweight from Neutral at JPMorgan
12/09/19 Barclays
Ipsen downgraded to Equal Weight from Overweight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.